T-1095

• Description :

  T-1095 is a selective and orally active Na+-glucose cotransporter (SGLT) inhibitor with IC50s of 22.8 μM and 2.3 μM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  SGLT

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/t-1095.html

• Purity :

  99.40

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  O=C(C(C(O)=C1)=C(C=C1C)O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]([C@H]2O)COC(OC)=O)CCC3=CC=C4C(C=CO4)=C3

• Molecular Formula :

  C26H28O11

• Molecular Weight :

  516.49

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]A Oku, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48 (9) :1794-800.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  SGLT1; SGLT2

• CAS Number :

  [209746-59-8]